Sommaire

• • ·FDA guidance helps facilitate drug co-development

    Page :109

     
• • ·Reducing xerostomia through advanced technology

    Page :110-111

    Andy Trotti, Avi Eisbruch

     
• • ·Personalised treatment for bladder cancer

    Page :111-112

    Torben F Ørntoft

     
• • ·Adjuvant interferon: recommit or move on?

    Page :112-113

    Ragini Kudchadkar, Vernon Sondak

     
• • ·Induction chemotherapy in head and neck cancer: closer to an answer?

    Page :113-114

    June Corry, Danny Rischin

     
• • ·Mood disorders in patients with cancer

    Page :114-115

    Elisabet Wasteson

     
• • ·Retraction—validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial

    Page :116

    Hervé Bonnefoi, Anil Potti, Mauro Delorenzi, Louis Mauriac, Mario Campone, Michèle Tubiana-Hulin, Thierry Petit, Philippe Rouanet, Jacek Jassem, Emmanuel Blot, Véronique Becette, Pierre Farmer, Sylvie André, Chaitanya R Acharya, Sayan Mukherjee, David Cameron, Jonas Bergh, Joseph R Nevins, Richard D Iggo

    
• • ·HPV types in early-onset cervical cancer

    Page :117

    Paolo Giorgi Rossi, Guglielmo Ronco

     
• • ·HPV types in early-onset cervical cancer – Authors’ reply

    Page :117-118

    Silvia de Sanjosé, Laia Alemany, Sara Tous, F Xavier Bosch, on behalf of the HPV RIS TT Study Group

    
• • ·Imatinib discontinuation: realistic for patients with chronic myeloid leukaemia achieving complete molecular remission?

    Page :118

    Fabio Stagno, Paolo Vigneri, Francesco Di Raimondo

    
• • ·Whole-brain radiotherapy in primary CNS lymphoma

    Page :118-119

    Andrés JM Ferreri, Lisa DeAngelis, Gerald Illerhaus, Brian P O’Neill, Michele Reni, Carole Soussain, Joachim Yahalom

    
• • ·Whole-brain radiotherapy in primary CNS lymphoma – Authors’ reply

    Page :119-120

    Agnieszka Korfel, Eckhard Thiel, Peter Martus, Michael Weller, for the German Primary CNS Lymphoma Study Group

     
• • ·Bortezomib-induced peripheral neuropathy: facts and genes

    Page :120-121

    Guido Cavaletti

    
• • ·Bortezomib-induced peripheral neuropathy: facts and genes – Authors’ reply

    Page :121

    Annemiek Broyl, Joost LM Jongen, Pieter Sonneveld

     
• • ·US urology clinics overprescribe prostate radiotherapy

    Page :122

    Bryant Furlow

    
• • ·Bowel cancer screening programme under threat in Australia

    Page :123

    Tamara Barrett

     
• • ·Nicotine replacement therapy offered to UK smokers

    Page :124

    Talha Burki

     
• • ·Networking: the new social revolution in health care

    Page :125

    Mario Christodoulou

     
• • ·Cancer pain: assessment, diagnosis, and management

    Page :126

    Irene J Higginson

     
• • ·Critical care: a nurse faces death, life, and everything in between

    Page :126

    Sian Maslin-Prothero

     
• • ·Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial

    Page :127-136

    Christopher M Nutting, James P Morden, Kevin J Harrington, Teresa Guerrero Urbano, Shreerang A Bhide, Catharine Clark, Elizabeth A Miles, Aisha B Miah, Kate Newbold, MaryAnne Tanay, Fawzi Adab, Sarah J Jefferies, Christopher Scrase, Beng K Yap, Roger P A’Hern, Mark A Sydenham, Marie Emson, Emma Hall, on behalf of the PARSPORT trial management group †

    Résumé Résumé Plan Plan   
• • ·A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment

    Page :137-143

    Steven Christopher Smith, Alexander Spyridon Baras, Garrett Dancik, Yuanbin Ru, Kuan-Fu Ding, Christopher A Moskaluk, Yves Fradet, Jan Lehmann, Michael Stöckle, Arndt Hartmann, Jae K Lee, Dan Theodorescu

    Résumé Résumé Plan Plan   
• • ·Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial

    Page :144-152

    Johan Hansson, Steinar Aamdal, Lars Bastholt, Yvonne Brandberg, Micaela Hernberg, Bo Nilsson, Ulrika Stierner, Hans von der Maase, for the Nordic Melanoma Cooperative Group

    Résumé Résumé Plan Plan   
• • ·Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial

    Page :153-159

    Jochen H Lorch, Olga Goloubeva, Robert I Haddad, Kevin Cullen, Nicholas Sarlis, Roy Tishler, Ming Tan, John Fasciano, Daniel E Sammartino, Marshall R Posner, for the TAX 324 Study Group *

    Résumé Résumé Plan Plan   
• • ·Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies

    Page :160-174

    Alex J Mitchell, Melissa Chan, Henna Bhatti, Marie Halton, Luigi Grassi, Christoffer Johansen, Nicholas Meader

    Résumé Résumé Plan Plan   
• • ·New driver mutations in non-small-cell lung cancer

    Page :175-180

    William Pao, Nicolas Girard

    Résumé Résumé Plan Plan  
• • ·Radionuclide and hybrid imaging of recurrent prostate cancer

    Page :181-191

    Ambros J Beer, Matthias Eiber, Michael Souvatzoglou, Markus Schwaiger, Bernd Joachim Krause

    Résumé Résumé Plan Plan  
• • ·Fertility-sparing surgery in patients with cervical cancer

    Page :192-200

    Lukas Rob, Petr Skapa, Helena Robova

    Résumé Résumé Plan Plan